Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1557802

This article is part of the Research Topic Community Series in Novel Reliable Approaches for Prediction and Clinical Decision-making in Cancer: Volume II View all 3 articles

Abnormally High expression of CHI3L1 in Peripheral Blood Mononuclear Cells and Serum and their Potential Diagnosis and Prediction from Lymphoma Patients

Provisionally accepted
Chao Wang Chao Wang 1Langui Tang Langui Tang 1Haibing Luo Haibing Luo 2Juan Liang Juan Liang 3Yanzhao Huang Yanzhao Huang 3Kaiyun Guo Kaiyun Guo 1Rong Liu Rong Liu 1Yuxing He Yuxing He 1Yan Gao Yan Gao 1*Ming Lei Ming Lei 1*
  • 1 The First People's Hospital of Changde City, Changde, Hunan Province, China
  • 2 Changde Fourth People's Hospital, changde, China
  • 3 Hengyang Medical College, University of South China, Hengyang, Hunan Province, China

The final, formatted version of the article will be published soon.

    This study aimed to investigate the expression of CHI3L1 in aggressive lymphomas and assess its potential as a diagnostic and prognostic biomarker.This study investigates the expression of CHI3L1 protein in the peripheral blood of patients with aggressive lymphoma and healthy controls using enzyme-linked immunosorbent assay (ELISA). The prognostic significance of CHI3L1 was assessed through Cox regression and Kaplan-Meier survival analyses. The differences in CHI3L1 expression between lymphoma and control samples were analyzed using the lymphoma-related gene expression datasets GSE25638 and GSE56315, as well as their combined dataset (GSE25638 and GSE56315). Subsequently, a prognostic analysis of CHI3L1 was conducted using the lymphoma tissue sample gene expression dataset GSE31312. Weighted gene co-expression network analysis (WGCNA) identified genes co-expressed with CHI3L1, and a protein-protein interaction (PPI) network was constructed. RT-qPCR was used to further validate CHI3L1 expression in peripheral blood mononuclear cells (PBMCs) from lymphoma patientsThe serum CHI3L1 protein expression in patients with aggressive lymphoma was significantly higher than that in healthy controls (p<0.001). Moreover, CHI3L1 levels were significantly elevated in stage III~IV patients compared to stage I~II patients (P = 0.001). One-way Cox regression and Kaplan-Meier analyses further demonstrated that high CHI3L1 expression was closely associated with shorter overall survival (p<0.001).Bioinformatics analysis revealed that CHI3L1 expression was significantly elevated in lymphoma samples compared to normal controls (p < 0.05), with diagnostic AUC values of 0.92, 0.99, and 0.93, indicating high diagnostic accuracy. Furthermore, patients with high CHI3L1 expression exhibited significantly shorter overall survival (p < 0.05), suggesting a potential association with poor prognosis. Co-expression analysis identified 605 genes associated with key biological processes, including the inflammatory response, signal transduction, and apoptosis. These genes were enriched in functional pathways such as mineral uptake and the Toll-like receptor signaling pathway.Validation experiments confirmed that CHI3L1 gene expression in PBMCs of patients with aggressive lymphoma was significantly higher than that in healthy individuals (p<0.01).This study demonstrates that elevated CHI3L1 expression is strongly associated with lymphoma onset, progression, severity, and poor prognosis, underscoring its potential as both a diagnostic and prognostic biomarker. Moreover, CHI3L1 may contribute to lymphoma progression by regulating key biological processes.

    Keywords: Lymphoma, CHI3L1, bioinformatics, overall survival, prognosis

    Received: 09 Jan 2025; Accepted: 17 Mar 2025.

    Copyright: © 2025 Wang, Tang, Luo, Liang, Huang, Guo, Liu, He, Gao and Lei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yan Gao, The First People's Hospital of Changde City, Changde, Hunan Province, China
    Ming Lei, The First People's Hospital of Changde City, Changde, Hunan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more